ERBB2 and neoplasm: Our experience with both ADAPT6 [22] and other HER2-targeting scaffold proteins, including affibody [26,30] and references therein and DARPins [33], demonstrated that injections of masses that were too low resulted in high uptake in tumours with low HER2 expression.